101 related articles for article (PubMed ID: 10660730)
1. [Chemotherapy based on EBM in the field of hematological malignancies].
Ogura M; Takeuchi H; Ueda R
Gan To Kagaku Ryoho; 2000 Jan; 27(1):14-29. PubMed ID: 10660730
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. [Chemotherapy of hematological malignancies based on EBM].
Ueda R
Nihon Naika Gakkai Zasshi; 2002 Mar; 91 Suppl():147-53. PubMed ID: 11989255
[No Abstract] [Full Text] [Related]
4. Fifth biannual report of the Cochrane Haematologic Malignancies Group--Focus on multiple myeloma.
Naumann F; Weingart O; Kruse E; Schulz H; Bohlius J; Hülsewede H; Engert A;
J Natl Cancer Inst; 2006 Aug; 98(16):E2. PubMed ID: 16912255
[No Abstract] [Full Text] [Related]
5. Fourth biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Hülsewede H; Bohlius J; Engert A
J Natl Cancer Inst; 2006 Apr; 98(8):E1. PubMed ID: 16622111
[No Abstract] [Full Text] [Related]
6. [Evidence-based medicine in cancer chemotherapy].
Ariyoshi Y
Gan To Kagaku Ryoho; 2000 Jan; 27(1):6-13. PubMed ID: 10660729
[TBL] [Abstract][Full Text] [Related]
7. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
8. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM
Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259
[TBL] [Abstract][Full Text] [Related]
9. [Hematologic tumors].
Ogawa M
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1416-21. PubMed ID: 14584273
[TBL] [Abstract][Full Text] [Related]
10. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Zinzani PL; Martelli M; Poletti V; Vitolo U; Gobbi PG; Chisesi T; Barosi G; Ferreri AJ; Marchetti M; Pimpinelli N; Tura S; ; ;
Haematologica; 2008 Sep; 93(9):1364-71. PubMed ID: 18603558
[TBL] [Abstract][Full Text] [Related]
11. [Histone deacetylase inhibitors in the treatment of hematological malignancies].
Lemal R; Ravinet A; Moluçon-Chabrot C; Bay JO; Guièze R
Bull Cancer; 2011 Aug; 98(8):867-78. PubMed ID: 21827981
[TBL] [Abstract][Full Text] [Related]
12. Biannual report of the Cochrane Haematological Malignancies Group.
Trelle S; Higgins G; Kober T; Engert A
J Natl Cancer Inst; 2004 Aug; 96(15):E2. PubMed ID: 15292394
[No Abstract] [Full Text] [Related]
13. Regional social system for specialized medical care in hematologic malignancies: a pilot study.
Takita M; Tanaka Y; Matsumura T; Kishi Y; Kodama Y; Nishimura T; Goto T; Nagai M; Kami M
Rural Remote Health; 2009; 9(3):1106. PubMed ID: 19637934
[TBL] [Abstract][Full Text] [Related]
14. [Quantitative-kinetic aspects of granulocytic resistance to infection in hematologic systemic diseases with reference to antineoplastic chemotherapy].
Sommer S
Z Arztl Fortbild (Jena); 1988; 82(11):513-5. PubMed ID: 3176536
[No Abstract] [Full Text] [Related]
15. Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma.
Weingart O; Rehan FA; Schulz H; Naumann F; Knauel I; Bohlius CB; Engert A
J Natl Cancer Inst; 2007 Sep; 99(17):E1. PubMed ID: 17728205
[No Abstract] [Full Text] [Related]
16. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
[TBL] [Abstract][Full Text] [Related]
17. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
Baron F; Gothot A; Salmon JP; Hermanne JP; Pierard GE; Fillet G; Beguin Y
Br J Haematol; 2000 Dec; 111(3):745-53. PubMed ID: 11122133
[TBL] [Abstract][Full Text] [Related]
18. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
19. [Second cancers in hematologic malignancies (epidemiologic observations from a 20-year period)].
Jakó J; Szerafin L; Nagy P
Orv Hetil; 2005 Mar; 146(10):461-9. PubMed ID: 15835344
[TBL] [Abstract][Full Text] [Related]
20. Third biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Skoetz N; Trelle S; Bohlius J; Engert A;
J Natl Cancer Inst; 2005 Aug; 97(16):E2. PubMed ID: 16106014
[No Abstract] [Full Text] [Related]
[Next] [New Search]
